H.J. Lenz

689 citations

24 papers · 551 indexed · 1 hit paper · h-index 9

Impact in

Oncology top 10%
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
Cancer Research

Papers in

Oncology 18
- Colorectal Cancer Treatments and Studies 14
- Cancer Treatment and Pharmacology 4
- Cancer-related Molecular Pathways 3
- Cancer Immunotherapy and Biomarkers 2
Cancer Research 5
- Cancer Genomics and Diagnostics 3

Co-authors: Dong‐Ho Park Kathleen D. Danenberg Fabio Gelsomino Arteid Memaj Massimo Aglietta Ka Yeung Mark Wong Ming Lei Sandzhar Abdullaev
Journals: Annals of Oncology (6 papers)Journal of Clinical Oncology (5 papers)The Pharmacogenomics Journal (3 papers)Seminars in Oncology (2 papers)International Journal of Radiation Oncology*Biology*Physics (1 paper)
Partner nations: United States Italy France

In The Last Decade

H.J. Lenz

23 papers receiving 537 citations

Hit Papers

align trajectories log scale

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 2022 · 154 citations

Peers

Countries citing papers authored by H.J. Lenz

Since Specialization

Citations

This map shows the geographic impact of H.J. Lenz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.J. Lenz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.J. Lenz more than expected).

Fields of papers citing papers by H.J. Lenz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.J. Lenz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.J. Lenz. The network helps show where H.J. Lenz may publish in the future.

Co-authorship network

The 25 scholars most cited alongside H.J. Lenz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H.J. Lenz Line = papers co-authored together H.J. Lenz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	LBA29 Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): New results from CheckMate 8HW Annals of Oncology ·韓鍾律, H.J. Lenz, Emanuel de Oliveira Andrade, 许顺良, E. Van Cutsem, Lawrence Phaller, Ben Boubker Rym, 真也藤江, Federico Rodriguez, John Rock Hadley, Arnaud de la Fouchardière, María Luisa Limón, Takashi Yoshino, J. Li, Carla Pittens, Elena Cela, Li Li, Rachel Tam, Yaxin Yi, I.V.S. Semyankin	2025	0
2	2O Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW Annals of Oncology ·Sara Lonardi, 真一大木, Dirk Arnold, Rocio García‐Carbonero, Myriam Chalabi, Hanako Aoki, H.J. Lenz, Lars Henrik Jensen, Rohit Joshi, Jeanine M.L. Roodhart, Takashi Yoshino, 李岫芬, Steven I. Blum, Jonathan T. Sims, W. J. F. van Oostveen, Fiona Taylor, Tai‐Tsang Chen, Elena Cela, Yaxin Yi, E. Van Cutsem	2024	2
3	541P Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW Annals of Oncology ·I.V.S. Semyankin, Sara Lonardi, H.J. Lenz, Lars Henrik Jensen, E. Van Cutsem, Lawrence Phaller, Ben Boubker Rym, 大治川浪, Federico Rodriguez, Michael Schenker, Arnaud de la Fouchardière, María Luisa Limón, 隆昌高橋, J. Li, José Luis Manzano Mozo, Elena Cela, Tai‐Tsang Chen, Ming Lei, Yaxin Yi, Hanako Aoki	2024	1
4	397P Early decreases in KRAS mutant allele frequency (MAF) predicts clinical benefit to the PLK1 inhibitor onvansertib in combination with FOLFIRI/bev in 2L treatment of metastatic colorectal carcinoma (mCRC) Annals of Oncology ·H.J. Lenz, H. E. Yi-Xuan, Lara Turza, Ю. Зашкола, Daniel H. Ahn	2022	1
5	Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 Annals of Oncology ·Thierry André, Sara Lonardi, Ka Yeung Mark Wong, H.J. Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Sandzhar Abdullaev, Arteid Memaj, Ming Lei, Michael F. Dixon, Scott Kopetz, Michael J. Overman Hit paper breakdown →	2022	154
6	550P Initial results of a phase Ia/Ib study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody in patients (pts) with advanced solid tumors Annals of Oncology ·Rishi Jain, Soraya Khezrzadeh, H.J. Lenz, Wells A. Messersmith, Vincent J. Picozzi, Muhammad Shaalan Beg, Benjamin A. Weinberg, Devalingam Mahalingam, Marc Drouin, سیده عشرت ایماندوست, Joshua S. Lichtman, Vadym Pakholchuk, Laura McDonald, Alex M. DePaoli, J. Zha, Andrew Hendifar	2021	4
7	Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen The Pharmacogenomics Journal ·Thomas Winder, Georgios Giamas, P. M. Wilson, W Zhang, Dongyun Yang, Pierre Bohanes, Y. Ning, Armin Gerger, Justin Stebbing, H.J. Lenz	2013	30
8	Time course of regorafenib-associated adverse events in the phase III CORRECT study Zeitschrift für Gastroenterologie ·Claudio Denzlinger, Axel Grothey, Anita Roth, Семин Дмитрий Игоревич, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Josep Tabernero, Tetsuhiro Yoshino, H.J. Lenz, V. Kentz Simonet, Frank Cihon, Dorothea Wagner, Dirk Laurent	2013	3
9	Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy The Pharmacogenomics Journal ·Wu Yueguang, Anthony B. El-Khoueiry, Dongyun Yang, W Zhang, Georg Lurje, Yan Ning, Thomas Winder, Zofia Wrosz, Shabnoor Iqbal, Kathleen D. Danenberg, Michael Kahn, 杨珅, Jabi E. Shriki, Justin Stebbing, H.J. Lenz	2012	39
10	An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence The Pharmacogenomics Journal ·Thomas Winder, P. M. Wilson, Dongyun Yang, W Zhang, Y. Ning, Derek G. Power, Pierre Bohanes, Armin Gerger, Laura H. Tang, Mira Shah, H.J. Lenz	2012	5
11	Randomisierte, doppelblinde, placebo-kontrollierte Phase III Multicenterstudie (CORRECT) von Regorafenib plus Best Supportive Care (BSC) versus Placebo plus BSC bei Patienten (Pat) mit metastasiertem kolorektalem Karzinom (mCRC), die nach einer Standardtherapie progredient waren Zeitschrift für Gastroenterologie ·Volker Heinemann, Axel Grothey, Anita Roth, Salvatore Siena, Alfredo Falcone, Marc Ychou, H.J. Lenz, Takayuki Yoshino, Frank Cihon, Anne Wagner, E. Van Cutsem	2012	1
12	Potential Role of Novel Wnt Modulator ICG-001 as a Radiosensitizer in Glioblastoma Cell Lines International Journal of Radiation OncologyBiologyPhysics ·Savita Dandapani, Nguyễn Văn Chào, Florence M. Hofman, Tsai‐Wen Chen, H.J. Lenz, Michaël Kahn, C.K. Hill, Ba Alassane	2012	2
13	Human epidermal growth factor receptor-2 (HER2) Ile655Val single nucleotide polymorphism (SNP) is associated with gender-specific outcome in patients with metastatic colorectal cancer (mCRC) treated with cetuximab in a phase II study (IMCL-0144). Journal of Clinical Oncology ·Armin Gerger, Pierre Bohanes, Dawei Yang, Thomas Winder, Yan Ning, Melissa J. LaBonte, David J. Mauro, Christiane Langer, Eric K. Rowinsky, H.J. Lenz	2011	3
14	Determinants of chemosensitivity in gastric cancer Current Opinion in Pharmacology ·Dong‐Ho Park, H.J. Lenz	2006	43
15	Genomic profiling as predictor of toxicity in patients with advanced colorectal cancer treated with platinum-based chemotherapy Journal of Clinical Oncology ·Danielle Roskelley, Jeong H. Yun, Dongyun Yang, Syma Iqbal, Oliver W. Press, Susan Groshen, Michael A. Gordon, N Degenkolb, H.J. Lenz	2004	1
16	Clinical update: proteasome inhibitors in solid tumors Cancer Treatment Reviews ·H.J. Lenz	2003	145
17	Pharmacogenomics in colorectal cancer Seminars in Oncology ·H.J. Lenz	2003	14
18	Cyclooxygenase-2 inhibitors in colorectal cancer Seminars in Oncology ·Zongfeng Yang, H.J. Lenz	2003	25
19	Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. PubMed ·Jingfang Ju, Debabrata Banerjee, H.J. Lenz, Kathleen D. Danenberg, Mifta Fauzan, Colin Paul Spears, Axel H. Schönthal, Sangem Rajesh, Daniel Hochhauser, Joseph R. Bertino, P. V. Danenberg	1998	29
20	Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. PubMed ·D. Banerjee, H.J. Lenz, Barbara Schnieders, Sangem Rajesh, Jingfang Ju, Colin Paul Spears, Daniel Hochhauser, Kathleen D. Danenberg, P. V. Danenberg, Bertino	1995	42

About H.J. Lenz

H.J. Lenz is a scholar working on Oncology, Cancer Research, Pathology and Forensic Medicine, Biotechnology and Pulmonary and Respiratory Medicine, having authored 24 papers that have together received 551 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (14 papers), Genetic factors in colorectal cancer (5 papers), Cancer Treatment and Pharmacology (4 papers), Cancer Genomics and Diagnostics (3 papers), Cancer-related Molecular Pathways (3 papers), Cancer Research and Treatments (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Estrogen and related hormone effects (2 papers). The work is most often cited by research in Oncology (366 citations), Cancer Research (91 citations), Pathology and Forensic Medicine (108 citations), Biotechnology (34 citations) and Molecular Biology (250 citations). H.J. Lenz has collaborated with scholars based in United States, Italy and France. Frequent co-authors include Dong‐Ho Park, Kathleen D. Danenberg, Fabio Gelsomino, Arteid Memaj, Massimo Aglietta, Ka Yeung Mark Wong, Ming Lei, Sandzhar Abdullaev, Bart Neyns and Thierry André. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, The Pharmacogenomics Journal, Seminars in Oncology and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact